China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Trump Says Anthropic No Longer Seen as National Security Threat 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
NEW YORK, Jan. 29, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased HeartWare International, Inc. (Nasdaq:HTWR) securities between June 10, 2014 and January 11, 2016.
Click here to learn about the case: http://docs.wongesq.com/HTWR-Info-Request-Form-1018. There is no cost or obligation to you.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/HTWR-Info-Request-Form-1018.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
